A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer when given as part of a chemotherapy/immunotherapy combination with or without a third drug, bevacizumab (brand names Avastin or Zirabev). The findings from an international clinical trial are reported in the new study led by co-first authors Emese Zsiros, MD, Ph.D., FACOG, Chair of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center and Nicoletta Colombo, MD, Ph.D., of the European Institute of Oncology in Milan, Italy.
This article was originally published on MedicalXpress.com
